Vectors derived from herpes simplex virus type 1 (HSV-1) have great potential for transducing therapeutic genes into the central nervous system; however, inefficient distribution of vector particles in vivo may limit their therapeutic potential in patients with gliomas. This study was performed to investigate the extent of HSV-1 amplicon vector-mediated gene expression in a threedimensional glioma model of multicellular spheroids by imaging highly infectious HSV-1 virions expressing green fluorescent protein (HSV-GFP). After infection or microscopy-guided vector injection of glioma spheroids at various spheroid sizes, injection pressures and injection times, the extent of HSV-1 vector-mediated gene expression was investigated via laser scanning microscopy. Infection of spheroids with HSV-GFP demonstrated a maximal depth of vector-mediated GFP expression at 70 to 80 mm. A . 80% transduction efficiency was reached only in small spheroids with a diameter of , 150 mm. Guided vector injection into the spheroids showed transduction efficiencies ranging between , 10 and . 90%. The results demonstrated that vector-mediated gene expression in glioma spheroids was strongly dependent on the mode of vector application-injection pressure and injection time being the most important parameters. The assessment of these vector application parameters in tissue models will contribute to the development of safe and efficient gene therapy protocols for clinical application.
I N VIEW OF the high incidence and poor prognosis of patients with malignant brain tumors treated by conventional therapies, research focusing on the elucidation of tumor biology and cell cycle regulation and on the establishment of clinically valuable gene therapies seems to be of the utmost importance. [1] [2] [3] The design of effective gene therapy strategies relies on concerted research to define the genetic and pathophysiologic alterations causing the disease, to understand the biologic characteristics of the target tissue, and to develop safe vectors and application systems to achieve efficient, targeted, and regulated alteration of specific therapeutic gene expression. 4, 5 The suicide gene therapy based on retroviral vector-mediated expression of herpes simplex virus type 1 thymidine kinase (HSV-1-TK) and subsequent ganciclovir application was successful in various experimental brain tumor models. 6, 7 Clinical studies revealed that this approach as an adjuvant to the surgical resection of recurrent high-grade brain tumors can be performed safely, although clinical responses were observed in only a few patients with small brain tumors. 8 The lack of therapeutic efficiency of this replication-deficient retrovirus vector system in clinical settings may be due to vector-producer cell instability but even more to the inability to distribute vector-producer cells throughout the tumor, the low transduction efficiency of retrovirions, and the heterogeneity of tumor tissue.
To circumvent some of these problems and to serve improved distribution of vector particles within tumor tissue, replication-competent oncolytic viral vectors and certain vector infusion and application methods are being used as part of a multimodal gene therapy approach. 4, [9] [10] [11] As the helper virus-free herpes simplex virus type 1 (HSV-1) amplicon is a safe and efficient vector system to transduce various central nervous system-derived cells, including human gliomas, 1, 12 it holds great promise as part of a multimodal virus/gene therapy approach in the future. Therefore, this study aimed to further investigate the potential of how well HSV-1 vector particles can be distributed in a three-dimensional glioma tissue by using multicellular spheroids (MCSs).
MCSs are a cell culture model well suited to studying micrometastasis, avascular regions of large tumors, and alterations in metabolites and gene expression. 13, 14 Moreover, the effects of radiation, chemotherapy, or immunotherapy can be efficiently tested in MCSs. [15] [16] [17] In comparison with single tumor cells grown in suspension or as monolayers, MCSs exhibit a higher complexity and, therefore, can be better compared to the situation in a three-dimensional tissue. 15 In addition, the vitality patterns of MCSs can be studied using confocal laser scanning microscopy (CLSM) and fluorescent dyes. 17 The aim of this study was to compare different methods of vector application and to investigate whether certain parameters of injection of HSV-1 vector particles into glioma MCSs would improve the extent of HSV-1 vectormediated gene expression. The MCS model of human Gli36 glioma cells was used to serve as three-dimensional tumor tissue in culture and was studied using CLSM.
Materials and Methods

Cell Culture
Human Gli36 glioma cells (provided by Dr. David Louis, Molecular Neurooncology Laboratory, Massachusetts General Hospital, Boston, MA) were grown as monolayers in Dulbecco's Modified Eagle medium (DMEM; Life Technologies, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (FBS; Roche Diagnostics, Mannheim, Germany) and 100 U/mL penicillin and 100 mg/mL streptomycin (P/S; Life Technologies). African green monkey kidney 2-2 cells (kindly provided by Dr. Rozanne Sandri-Goldin, University of California Irvine) were grown in DMEM supplemented with 10% FBS, 1% P/S, and 500 mg/mL G418 (Life Technologies). Human DU-145 prostate cancer cells (provided by Dr. J. Carlsson, Uppsala, Sweden) were cultured in F10 medium (Life Technologies) supplemented with 10% FBS and 1% P/S. All cells were cultured at 37uC in a 5% CO 2 /95% air atmosphere.
Spheroid Culture
MCSs were established from human Gli36 glioma and human DU-145 prostate cancer. Spheroids were grown from single cells. Cell monolayers were trypsinized with 0.2% trypsin and 0.05% ethylenediaminetetraacetic acid (INC Flow, Meckenheim, Germany) and seeded in 250 mL siliconated spinner flasks (Integra Bioscience, Fernwald, Germany) with 250 mL complete medium agitated at 40 rpm using a stirrer system (Integra Bioscience, Fernwald, Germany). Spheroids were cultured in DMEM supplemented with 10% FBS and 1% P/S, 2 mM glutamine (Life Technologies), and 100 mM b-mercaptoethanol (Sigma Aldrich, Taufkirchen, Germany) at 37uC in a 5% CO 2 /95% air atmosphere. The medium was replaced daily.
HSV-1 Amplicon Plasmid Construction and Helper Virus-Free Packaging of HSV-1 Amplicons
The HSV-1 amplicon plasmid pHSV-GN (obtained from X.O. Breakefield, Neurogenetics Unit, Massachusetts General Hospital 18 ) carries the green fluorescence protein gene (gfp) under transcriptional control of a cytomegalovirus immediate early gene promoter (CMV 12 ). After packaging, the gfp-transducing HSV-1 amplicon vector particles are depicted as HSV-GFP. Helper virus-free stocks of HSV-GFP amplicons were generated as described previously. 19, 20 In brief, 10 cm plates were seeded with 3.6 3 10 6 vero 2-2 cells. Sixteen hours later, the cells were transfected with 6 mg of Pac1 digested cosmids and 1.8 mg of the respective HSV-1 amplicon plasmid using lipofectamine (Life Technologies) for 5.5 hours. Thereafter, cells were washed (serum-free medium; three times) and incubated in 10 mL packaging medium (DMEM, 6% FBS, 25 mM HEPES [pH 7.3]) at 37uC for 24 hours. Thereafter, the medium was replaced by fresh packaging medium and cells were incubated for 24 hours at 34uC and then for 24 hours at 37uC. After harvesting (72-80 hours after transfection), vector stocks were purified and concentrated. The virus pellet was resuspended in phosphatebuffered saline (PBS), and virus stocks were stored at 280uC for titration and final use. Purified vector stocks were titered (transducing units per milliliter [TU/mL]) on 2-2 and Gli36 cells by infecting confluent monolayers in 24-well plates (Falcon, Becton Dickinson, Heidelberg, Germany) and counting GFP-positive cells 24 hours later. Vector titers of 1 to 4 3 10 8 TU/mL were used for further experiments.
GFP Fluorescence and Quantification
For determination of green fluorescence, human Gli36 cells were plated in 24-well plates (2 3 10 5 cells/well) to form confluent monolayers and were infected with HSV-GFP at a multiplicity of infection of 1 the next day. GFP-expressing cells were examined by use of a standard fluorescence microscope (Zeiss Axiovert 135, Carl Zeiss, Heidenheim, Germany) 24 hours after infection. 20 
Characterization of Viable Target Tissue within Glioma Spheroids
To identify viable glioma tissue and to distinguish this from necrosis, staining with Lucifer yellow and Ki-67 was performed. 21 
Lucifer Yellow
The highly charged polar tracer Lucifer yellow (Sigma, Deishofen, Germany) was used to stain lethal cells within necrotic areas. 21 Incubation of MCSs with Lucifer yellow (20 mM) was performed for 40 minutes at room temperature. The spheroids were washed in PBS three times, placed in DMEM, and examined by CLSM (excitation by 488 nm line of an argon-ion laser, LP 515 nm emission filter set).
Ki-67
The mouse monoclonal Ki-67 antibody (Boehringer, Mannheim, Germany) recognizes a cell cycle-associated protein of 345 kDa identical to the Ki-67 antigen. The immunoreactivity of Ki-67 is confined to the nuclei of proliferating cells. The Ki-67 antigen is preferentially expressed during late G 1 , S, G 2 , and M phases of the cell cycle, whereas resting, noncycling cells (G 0 phase) lack Ki-67 expression. For Ki-67 staining, MCSs were fixed in ice-cold methanol/acetone (30 minutes at 220uC), washed (PBS with 0.1% Triton X10), embedded in Tissue Tek (Reichert-Jung, Heidelberg, Germany), and frozen in liquid nitrogen. Cryosections of 12 mm were performed on a Reichert-Jung 2800 Frigocut. Sections were mounted, blocked against unspecific binding of MCSs (1% BSA 60 minutes), incubated with 7.5 mg/mL Ki-67 antibody (60 minutes), washed three times, and incubated with 4.6 mg/mL Cy5-conjugated F(ab9) 2 fragment goat antimouse IgG (Boehringer) (60 minutes). Ki-67-positive nuclei were visualized by CLSM using fluorescence excitation at 633 nm (helium-neon-laser) and a longpass 655 nm filter set.
Infection versus Injection of Spheroids
Spheroids were either infected with 5 3 10 6 TU HSV-GFP amplicon vector or directly injected by use of a microinjector (Eppendorf, Hamburg, Germany) at various spheroid sizes (diameter 100-800 mm), injection pressures (50, 100, 300, 1,000 hPa), and injection times (5, 15 , 45 seconds). The extent of HSV-1 amplicon vector-mediated gene expression was investigated by use of CLSM (CLSM 410 microscope, Zeiss, Jena, Germany) one day after vector application. Ten-micrometer slices were acquired starting at the surface of the spheroid for a maximal depth of 160 mm. After infection, the maximum depth of GFP expression was registered using the CLSM imaging analysis software. After injection, the slice nearest the equatorial plane was used to evaluate the extent of vector-mediated gene expression by means of a regions of interest (ROI) analysis using the CLSM imaging analysis software. The volume of transduced tumor tissue was calculated by 4/3*p *r 3 . For each infection experiment, 15 to 20 spheroids were investigated. For each injection experiment, 3 to 6 spheroids were investigated for each parameter. Experiments were repeated three times. Targeted spheroid injections were performed by holding the spheroid by a sterile vacuum tip (diameter 100 mm) and by injecting HSV-GFP amplicon vector via the transfer tip spike (diameter 20 mm) into the center of the spheroid.
CLSM and Optical Probe Technique
MCSs were investigated under the optical control of an inverted CLSM (LSM 410, Zeiss) using a 253 objective as described previously. 17, 22 The CLSM allows detection of fluorescence signals up to a depth of 180 mm in living tissue. To investigate the extent of vector-mediated expression, the optical probe technique was used. The principle of the optical probe technique is that fluorescence intensity is recorded within a selected ROI (600 mm 2 , 40 3 40 pixels) along the radial axis starting in the center of the spheroid and moving to the periphery. The motor commands of the stepper motor of the confocal setup were set to steps of 10 mm in zdirection between two adjacent ROI. The pinhole settings of the confocal setup were chosen to give a full-width half-maximum of 8 mm. Each ROI was scanned once for 0.064 seconds. A whole z-series of 16 ROI was achieved in approximately 7 seconds, the convolution time of the stepper motor thereby being the rate-limiting step. The mean field intensity of the fluorescence signal was determined in each ROI, and the fluorescence intensity data were plotted as a function of the penetration depth of the laser beam in the tissue.
Statistics
Analysis of variance (ANOVA) was performed by Superior Performance Software, SPSS, version 10.0 for Windows (SPSS Inc., UK Ltd, Surrey, England), and for regression analysis, KaleidaGraph 3.08 (Synergy Software, Reading, PA) was used.
Results
A new three-dimensional tumor spheroid model from human Gli36 glioma cells was established to determine injection parameters for HSV-1 vector particles that lead to an improved distribution of vector-mediated gene expression. Spheroids were grown in spinner flasks for up to 22 days, and spheroid sizes were measured every day. The growth curve ( Figure 1A ) of human Gli36 glioma spheroids demonstrates that an exponential growth is kept for at least 18 days and that the size of spheroids derived from human Gli36 glioma cells may reach a diameter of up to 1,000 mm. In comparison, control spheroids grown from human DU-145 prostate cancer cells reach a size of up to 400 mm in diameter.
To characterize the physiologic status and viability of human Gli36 glioma spheroids, Lucifer yellow and Ki-67 staining was performed ( Figure 1, B and C) . The critical diameter for the first appearance of necrotic areas in Gli36 spheroids was greater than 600 mm. In comparison, signs of necrosis were found in control DU-145 prostate cancer spheroids at a diameter of . 300 mm. Proliferating tumor cells were found throughout the spheroid at a diameter of , 300 mm or at the surface for those spheroids with diameters . 300 mm.
To determine the extent of vector-mediated GFP expression after incubation of spheroids with vector particles (infection), multiple spheroids were investigated by CLSM 24 hours after infection of spheroids with 4 3 10 6 TU HSV-GFP amplicons (24-well plate, total infection volume 200 mL). The maximal depth of vector-mediated GFP-expression was 70 to 80 mm, as measured from the surface, with maximum levels of GFP expression at 40 to 50 mm ( Figure 2, A and B) . These results were independent of the size of the spheroid, resulting in relatively lower transduction efficiency with increasing spheroid size ( Figure 2C) . A . 60% transduction efficiency was reached only in small spheroids with a radius of less than 150 mm. Owing to the lower transduction efficiency of HSV-1 vector particles into human DU-145 prostate cancer cells, only single DU-145 cells at the surface of DU-145 spheroids were GFP positive.
To improve transduction efficiency in larger spheroids, guided vector injections were performed by use of a micromanipulator ( Figure 3A) . A spheroid was fixed by use of a vacuum tip, and the transfer tip was placed into the center of the spheroid using an automatic guidance system. Figure 3A shows examples of the guided injections of vector and control dye (methylene blue). After guided vector injection into the spheroids, injection time-and injection pressure-dependent transduction efficiencies ranged between , 10% and . 90%. The maximal transduction efficiencies were reached at injection pressures of 100 hPa for smaller spheroids (3 days) to 300 hPa for larger spheroids (7-10 days) (ANOVA; p , .05; Figure 3B ). Moreover, injection time-dependent increases in vector distribution were observed at 50 hPa at all spheroid ages (3, 7, and 10 days) and at 100 hPa and 300 hPa only at larger spheroids (10 and 7 days, respectively) ( Figure 3C ). Using a higher pressure (1,000 hPa) failed to further increase the transduction rate, most likely owing to leakage from the injection site. A further increase in the time period for injection (over 45 seconds) in the same location of the transfer tip did not have a positive effect on the transduction rate, which may be due to saturation or obstruction of the interstitial space by vector particles. In comparison with infection, especially in larger spheroids, higher transduction efficiency could be reached only by targeted microinjection (Figure 4 ).
Discussion
The purpose of this study was to establish a threedimensional human glioma model in culture using the human glioma Gli36 cell line to investigate vector distribution and transduction efficiency by use of HSV-1 amplicon vectors employing different vector application methods. Injection time-and pressure-dependent increase in transduction efficiency could be achieved compared to infection. This type of study might be important for planning vector applications in animal models and in the clinical application to serve for optimal vector distribution in vivo.
With regard to spheroid characterization, the viability and proliferative activity of human Gli36 glioma spheroids could be demonstrated even in larger spheroids by Ki-67 staining. 21, 23 The Gli36 spheroids provide a stable model to study targeted three-dimensional vector application. As had been shown in a previous study, Gli36 glioma spheroids reach a considerably larger size than DU145 prostate cancer spheroids. 24 The distribution of vectormediated gene expression was investigated by use of the optical probe technique. This technique permits the quantitative noninvasive analysis of the distribution of HSV-1 viral particle in MCSs by means of CLSM. 23 The glioma spheroids in culture can be compared to gliomas grown in vivo with respect to their three-dimensional tumor structures, which exhibit a higher complexity than those of single tumor cells grown in suspension or monolayers. Therefore, new methods with regard to targeted application of vector particles can be tested in these three-dimensional models before taking the step into A B C Figure 1 . Characterization of three-dimensional spheroids. A, Growth curve of human Gli36 glioma spheroids. Human Gli36 glioma spheroids were grown for 22 days in a spinner flask, and their size was recorded over time. An exponential growth was observed for at least 18 days. B, Lucifer yellow staining. Lucifer yellow was used to stain lethal cells within necrotic areas. Different age and size stages of human Gli36 glioma spheroids are shown in comparison with DU-145 prostate cancer spheroids incubated with Lucifer yellow. The critical diameter for the first appearance of necrotic areas proved to be greater than 900 mm for human Gli36 glioma spheroids and greater than 350 mm for control DU-145 spheroids. C, Ki-67 immunostaining. Ki-67 expression indicates that multicellular spheroids of various sizes consist mostly of proliferating cells up to day 4 and a rim of proliferating tumor cells at larger spheroid sizes. In comparison, Ki-67 staining is shown in a 7-day-old DU-145 prostate spheroid.
animal models or human application in vivo. It should be pointed out that not every cell line is able to form spheroids and that spheroids in culture may contain glioma cells, astrocytes, neurons, and blood vessels. 13, 25 Several gene therapy studies indicate that gene transfer with regard to distribution of vector particles within solid tumors is one of the main limiting factors. [26] [27] [28] For safe and efficient gene therapy in clinical application, technology is required that allows the noninvasive monitoring of the level and distribution of vector-mediated gene expression in vivo. With the help of imaging, one could follow critical steps of the gene therapy protocol, such as vector distribution volume 29 and the tissue dose of vectormediated gene expression in vivo. 20, 28, 29 Furthermore, the delivery and function of the therapeutic gene HSV-1-TK using HSV amplicon vectors have been demonstrated in subcutaneous gliomas in nude mice 19 ; however, vector distribution within the tumor still needs to be improved. In recent years, the group of Bankiewicz, as discussed in reference 30, investigated and improved the use of convection-enhanced delivery (CED) as a method to deliver therapeutics (in particular liposomes) to the central nervous system. They further developed a magnetic resonance imaging-based imaging approach whereby gadolinium-loaded liposomes were coinfused with therapeutic agents 30 to visualize their delivery.
For the spheroid model, we could demonstrate that the efficiency of HSV-1 amplicon vector-mediated gene expression is dependent on application parameters such as time, pressure, and volume, which seem to be critical to reach efficient gene expression. Another way to improve the distribution of vector-mediated gene expression is to use either replication-conditional HSV-1 vectors 1, 31 containing retrovirus vector components to achieve amplification of stable transgene expression in tumors by conversion of tumor cells into retroviral producer cells. 32 In our infection studies using HSV-1 amplicons, we demonstrated that the maximal depth of vector-mediated GFP expression is 70 to 80 mm from the surface of the spheroid. The reason for the limited transduction efficiency of Gli36 spheroids is most likely due to the limited penetration of HSV-1 vector particles within the three-dimensional tumor tissue. Similar results were observed by using adenovirus vectors. 27 Obviously, the particle size, constitution of the extracellular space, and expression of cell surface receptors of the vector particle seem to play critical roles. Adeno-associated virus (AAV)based vectors are very small particles (20 nm) compared to AdV (80 nm) and HSV-1 (250 nm).
or herpes simplex virus/Epstein-Barr virus hybrid amplicon vectors
Hadaczek and colleagues showed that CED of AAV-based vectors resulted in a significantly improved distribution of AAV vectormediated gene expression when compared to simple injection techniques in nonhuman primates. 33 Most importantly, blocking AAV receptors at the neuronal membrane by heparin extended vector distribution and resulted in a significantly larger area of transduction of a rat brain. Enger and colleagues used AAV-and AdV-based vectors and demonstrated the dependency of vectormediated gene expression on the mode of vector application using CLSM. 27 We also demonstrated that transduction efficiency could be significantly improved by application of HSV-1 amplicon vectors using a micromanipulator. By varying the time and injection pressure for application of vector particles into the spheroids, the transduced spheroid volume could be significantly improved, especially in older or larger spheroids. However, 100% transduction efficiency could not be reached. In contrast, Betz and colleagues investigated the effects of infusion parameters, infectious titers, and virus concentration on transduction volume by gene transfer to rodent brain using recombinant adenoviral vectors and came to the conclusion that changes of infusion parameters have only limited effects on transduction efficiency. 34 However, other findings report the effect of variables affecting, for example, AAV CED, such as rate of infusion; optimal cannula size, type, or placement; infusion volume; and viral serotype. [35] [36] [37] [38] The discrepant findings between different studies indicate that the lack of widespread vector distribution throughout the tumor tissue is still one of the current limitations for successful clinical application of gene therapy vectors. Therefore, various modes of vector application should be tested in three-dimensional tumor models for each specific vector, which will be applied in clinical application to serve for the determination of application parameters that lead to optimal vector distribution and gene transduction.
With regard to clinical applicability and ''potential use,'' we would like to point out that normal intracranial pressure is 0 to 10 mm Hg. The injection pressures used in our work (50, 100, 300, 1,000 hPa) are equivalent to 37.5, 75, 250, and 750 mm Hg, respectively. Up to now, only CED has been successfully used by our group to deliver vector particles into patients with gliomas. 29 Unlike local injection techniques, CED uses a pressure gradient established at the tip of an infusion catheter that literally pushes the infusate through the interstitial space. 39 With 50 to 100 hPa (37.5-75 mm Hg), we seem to be at the same infusion line pressures described by Bobo and colleagues in their initial studies of CED, but with higher pressures, we may be at the limit of clinical tolerance. 40 
Conclusion
Our results demonstrate that the extent of HSV-1 amplicon vector-mediated gene expression in threedimensional human Gli36 glioma spheroids is greatly dependent on the mode of vector application (infection versus injection)-injection pressure and injection time being the most important parameters. The assessment of vector application parameters in tissue models will contribute to the development of safe and efficient gene therapy and vector application protocols for clinical application. A combination of novel modes of vector delivery and improved vector systems shall increase the level of clinical relevance.
